A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster

Sponsor
Yung Shin Pharm. Ind. Co., Ltd.
Study ID
NCT02152800
Phase
PHASE4
Status
Completed

Conditions

  • Herpes Zoster

Eligibility Criteria

Sex
ALL
Age
20 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to compare the safety and efficacy of Vacyless® and Valtrex® in patients with acute herpes zoster.

Key Dates

Start date
Apr 30, 2011
Status verified
May 2014
Primary completion
Sep 30, 2013
Completion
Nov 30, 2013

Study Design

Enrollment
25 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Vacyless® 1000 mg
    one Vacyless® 1000 mg tablets, 3 times daily for 7days
  • Experimental: Vacyless® 500mg
    Two Vacyless® 500mg tablets, 3 times daily for 7 days
  • Active Comparator: Valtrex® 500 mg
    Two Valtrex® 500 mg tablets, 3 times daily for 7days

Primary Outcome Measure

the rash severity, in terms of rash counts [ Time Frame: Day 28 ]

Related Studies